|
STRADB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62458935193399E-12 |
| Normal-vs-Stage2 |
5.406200E-04 |
| Normal-vs-Stage3 |
1.47659662275146E-14 |
| Normal-vs-Stage4 |
5.62305757512149E-12 |
| Stage1-vs-Stage2 |
1.018570E-03 |
| Stage1-vs-Stage3 |
2.640000E-01 |
| Stage1-vs-Stage4 |
3.382800E-01 |
| Stage2-vs-Stage3 |
1.815740E-02 |
| Stage2-vs-Stage4 |
3.648300E-04 |
| Stage3-vs-Stage4 |
9.010200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.363480E-03 |
| Normal-vs-Asian |
1.47950540707598E-11 |
| Caucasian-vs-AfricanAmerican |
6.992600E-01 |
| Caucasian-vs-Asian |
6.682000E-01 |
| AfricanAmerican-vs-Asian |
6.029000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6242562850266E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
8.209400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
3.78560516267612E-11 |
| Normal-vs-Age(81-100Yrs) |
1.905200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.453800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.387960E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.478200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.888400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.757900E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.999000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.343000E-01 |
| Classical-VS-Follicular |
1.11022302462516E-16 |
| Classical-VS-Other |
8.126800E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.77760028918783E-10 |
| Tall-VS-Other |
3.969800E-01 |
| Tall-VS-Normal |
6.77200517884557E-11 |
| Follicular-VS-Other |
8.160300E-03 |
| Follicular-VS-Normal |
1.540090E-03 |
| Other-VS-Normal |
2.807900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.6242562850266E-12 |
| Normal-vs-N1 |
1.50635059981141E-12 |
| N0-vs-N1 |
9.029700E-04 |
|
|
